Replay available

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Call

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) Q1 2025 earnings conference call, held 2025-05-12. Replay captured from the company's public earnings webcast.

Mon, May 12, 2025 at 4:30 PMendedReplay
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dan Ferry

Vice President, Investor Relations

John Colleton

Chief Executive Officer

Dr. David Rodman

Chief Medical Officer

Adam Levy

Chief Financial Officer

Michael DeFury

Analyst, Evercore

Richard Law

Analyst, Goldman Sachs

Themis Fernandez

Analyst, Guggenheim Partners

Tim Anderson

Analyst, Bank of America

Annabelle Samimi

Analyst, Stiefel

Mohit Bansal

Analyst, Wells Fargo

Rami Kakuta

Analyst, LifeSci Capital

Replay transcript excerpt

Thank you. Good afternoon, ladies and gentlemen, and welcome to the Mineralis first quarter 2025 earnings conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Monday, May 12th of 2025. I would now like to turn the conference over to Dan Ferry. Please go ahead. Thank you, Aubrey. I would like to welcome everyone joining us today for our first quarter 2025 conference call. Earlier this afternoon, we issued a press release providing our first quarter 2025 financial results and business updates. A replay of today's call will be available on the investor section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K, and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, May 12, 2025, and as except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to John Colleton, Chief Executive Officer of Mineral H...

More from Mineralys Therapeutics, Inc.